ALEC
Alector
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 855.64M; Volume: 1.02M; AvgVol 3m: 950.35K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.03; EPS growth quarter/prev quarter: -58.50%;
EPS growth this year: -125.00%; EPS growth past 5 years: ;
EPS ttm: -2.03;
P/S: 43.48; P/B: 2.27; P/Cashflow: 1.64; P/FCF: ;
Sales: 19.04M; Sales growth quarter/prev quarter: -53.60%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -28.60%; ROE – return on equity: -50.90%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.00%; Insider Transactions:-39.81%;
Institutional Ownership: 79.60%; Institutional Transactions: 2.82%;
Data update: 07.10.2020.